MiMedx Group, Inc. (NASDAQ:MDXG) Given Consensus Rating of “Buy” by Analysts

Shares of MiMedx Group, Inc. (NASDAQ:MDXG) have earned an average recommendation of “Buy” from the five ratings firms that are currently covering the stock, MarketBeat.com reports. Five equities research analysts have rated the stock with a buy recommendation. The average twelve-month price objective among brokerages that have updated their coverage on the stock in the last year is $12.00.

Separately, StockNews.com lowered MiMedx Group from a “strong-buy” rating to a “buy” rating in a report on Friday, November 8th.

Hedge Funds Weigh In On MiMedx Group

Several institutional investors and hedge funds have recently bought and sold shares of MDXG. Isthmus Partners LLC grew its holdings in MiMedx Group by 30.4% during the second quarter. Isthmus Partners LLC now owns 393,214 shares of the company’s stock valued at $27,000 after purchasing an additional 91,714 shares during the period. Blue Trust Inc. bought a new position in MiMedx Group during the third quarter valued at $30,000. Point72 Asset Management L.P. bought a new position in MiMedx Group during the second quarter valued at $40,000. Point72 DIFC Ltd grew its holdings in MiMedx Group by 127.6% during the third quarter. Point72 DIFC Ltd now owns 7,626 shares of the company’s stock valued at $45,000 after purchasing an additional 4,275 shares during the period. Finally, Entropy Technologies LP bought a new position in MiMedx Group during the third quarter valued at $64,000. 79.15% of the stock is owned by institutional investors.

MiMedx Group Stock Performance

Shares of MiMedx Group stock opened at $9.68 on Friday. The company has a market cap of $1.42 billion, a PE ratio of 17.60 and a beta of 1.98. MiMedx Group has a 52 week low of $5.47 and a 52 week high of $9.71. The business has a 50 day moving average price of $7.20 and a 200-day moving average price of $6.95. The company has a quick ratio of 3.53, a current ratio of 4.10 and a debt-to-equity ratio of 0.10.

About MiMedx Group

MiMedx Group, Inc develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue’s inherent biological properties and regulatory proteins.